Gregory D Huhn1, Gordon Crofoot2, Moti Ramgopal3, Joseph Gathe4, Robert Bolan5, Donghan Luo6, Richard Bruce Simonson7, Richard E Nettles7, Carmela Benson7, Keith Dunn7. 1. Ruth M. Rothstein CORE Center, Chicago, Illinois, USA. 2. Crofoot Research Center, Houston, Texas, USA. 3. Midway Immunology and Research Center, Fort Pierce, Florida, USA. 4. Therapeutic Concepts, Houston, Texas, USA. 5. Los Angeles LGBT Center, Los Angeles, California, USA. 6. Janssen Research & Development, LLC, Titusville, New Jersey, USA. 7. Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
Abstract
BACKGROUND: Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a phase 3 prospective study evaluating efficacy/safety of a single-tablet regimen in a rapid-initiation model of care. METHODS: Adults aged ≥18 years began D/C/F/TAF ≤14 days from diagnosis without screening/baseline results; as results became available, participants not meeting predefined safety/resistance stopping rules continued. Primary endpoint was virologic response (HIV-1 RNA <50 copies/mL; intent-to-treat; US Food and Drug Administration [FDA] snapshot) at week 48; participant satisfaction was measured via the HIV Treatment Satisfaction Questionnaire status version (HIVTSQs). RESULTS: Of 109 participants, 87% were male, 32% black/African American, median (range) age was 28 (range, 19-66) years, 25% of participants had HIV-1 RNA ≥100 000 copies/mL, 21% had CD4+ cell count <200 cells/µL, and 31% enrolled ≤48 hours from diagnosis. At week 48, 97 (89%) participants completed the study and 92 (84%) achieved HIV-1 RNA <50 copies/mL (FDA snapshot). There were no protocol-defined virologic failures; incidences of adverse events (AEs) and adverse drug reactions (33%) were low, no serious AEs were study drug related, and 1 (<1%) participant discontinued due to study drug related AE(s). The overall HIVTSQs score at week 48 was 58 (maximum: 60). CONCLUSIONS: At week 48, a high proportion of participants starting D/C/F/TAF achieved HIV-1 RNA <50 copies/mL and very few discontinued therapy. D/C/F/TAF was well tolerated, no participants discontinued due to baseline resistance stopping criteria, and high treatment satisfaction among participants was recorded. CLINICAL TRIALS REGISTRATION: NCT03227861.
BACKGROUND: Most guidelines recommend rapid treatment initiation for patients with newly diagnosed humanimmunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a phase 3 prospective study evaluating efficacy/safety of a single-tablet regimen in a rapid-initiation model of care. METHODS: Adults aged ≥18 years began D/C/F/TAF ≤14 days from diagnosis without screening/baseline results; as results became available, participants not meeting predefined safety/resistance stopping rules continued. Primary endpoint was virologic response (HIV-1 RNA <50 copies/mL; intent-to-treat; US Food and Drug Administration [FDA] snapshot) at week 48; participant satisfaction was measured via the HIV Treatment Satisfaction Questionnaire status version (HIVTSQs). RESULTS: Of 109 participants, 87% were male, 32% black/African American, median (range) age was 28 (range, 19-66) years, 25% of participants had HIV-1 RNA ≥100 000 copies/mL, 21% had CD4+ cell count <200 cells/µL, and 31% enrolled ≤48 hours from diagnosis. At week 48, 97 (89%) participants completed the study and 92 (84%) achieved HIV-1 RNA <50 copies/mL (FDA snapshot). There were no protocol-defined virologic failures; incidences of adverse events (AEs) and adverse drug reactions (33%) were low, no serious AEs were study drug related, and 1 (<1%) participant discontinued due to study drug related AE(s). The overall HIVTSQs score at week 48 was 58 (maximum: 60). CONCLUSIONS: At week 48, a high proportion of participants starting D/C/F/TAF achieved HIV-1 RNA <50 copies/mL and very few discontinued therapy. D/C/F/TAF was well tolerated, no participants discontinued due to baseline resistance stopping criteria, and high treatment satisfaction among participants was recorded. CLINICAL TRIALS REGISTRATION: NCT03227861.
Authors: Niklaus D Labhardt; Isaac Ringera; Thabo I Lejone; Thomas Klimkait; Josephine Muhairwe; Alain Amstutz; Tracy R Glass Journal: JAMA Date: 2018-03-20 Impact factor: 56.272
Authors: Hans-Jürgen Stellbrink; José R Arribas; Jeffrey L Stephens; Helmut Albrecht; Paul E Sax; Franco Maggiolo; Catherine Creticos; Claudia T Martorell; Xuelian Wei; Rima Acosta; Sean E Collins; Diana Brainard; Hal Martin Journal: Lancet HIV Date: 2019-05-05 Impact factor: 12.767
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Sydney Rosen; Mhairi Maskew; Matthew P Fox; Cynthia Nyoni; Constance Mongwenyana; Given Malete; Ian Sanne; Dorah Bokaba; Celeste Sauls; Julia Rohr; Lawrence Long Journal: PLoS Med Date: 2016-05-10 Impact factor: 11.069
Authors: Joseph J Eron; Chloe Orkin; Joel Gallant; Jean-Michel Molina; Eugenia Negredo; Andrea Antinori; Anthony Mills; Jacques Reynes; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; John Jezorwski; Simon Vanveggel; Magda Opsomer Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Jonathan Colasanti; Jeri Sumitani; C Christina Mehta; Yiran Zhang; Minh Ly Nguyen; Carlos Del Rio; Wendy S Armstrong Journal: Open Forum Infect Dis Date: 2018-06-28 Impact factor: 3.835
Authors: Erkki Lathouwers; Eric Y Wong; Kimberley Brown; Bryan Baugh; Anne Ghys; John Jezorwski; El Ghazi Mohsine; Erika Van Landuyt; Magda Opsomer; Sandra De Meyer Journal: AIDS Res Hum Retroviruses Date: 2019-10-21 Impact factor: 2.205
Authors: Keith Dunn; Bryan Baugh; Nika Bejou; Donghan Luo; Jennifer Campbell; Sareh Seyedkazemi; David Anderson Journal: J Int Assoc Provid AIDS Care Date: 2022 Jan-Dec
Authors: Carmen Hidalgo-Tenorio; Juan Pasquau; David Vinuesa; Sergio Ferra; Alberto Terrón; Isabel SanJoaquín; Antoni Payeras; Onofre Juan Martínez; Miguel Ángel López-Ruz; Mohamed Omar; Javier de la Torre-Lima; Ana López-Lirola; Jesús Palomares; José Ramón Blanco; Marta Montero; Coral García-Vallecillos Journal: Viruses Date: 2022-03-04 Impact factor: 5.048
Authors: Charlotte-Paige Rolle; Mezgebe Berhe; Tulika Singh; Roberto Ortiz; Anson Wurapa; Moti Ramgopal; Peter A Leone; Jessica E Matthews; Marybeth Dalessandro; Mark R Underwood; Konstantinos Angelis; Brian R Wynne; Deanna Merrill; Christopher Nguyen; Jean van Wyk; Andrew R Zolopa Journal: AIDS Date: 2021-10-01 Impact factor: 4.177